Fabiana Alves Selected Research

Paromomycin (Paromomycin Sulfate)

11/2021	Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.
1/2019	Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
10/2018	Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.
5/2017	Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
3/2017	Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fabiana Alves Research Topics

Disease

21	Visceral Leishmaniasis (Kala Azar) 10/2022 - 01/2015
4	Infections 01/2020 - 06/2011
3	Leishmaniasis 08/2022 - 01/2020
2	Myositis Ossificans (Fibrodysplasia Ossificans Progressiva) 08/2021 - 02/2019
2	Renal Insufficiency (Renal Failure) 01/2019 - 01/2015
2	Chagas Disease (American Trypanosomiasis) 01/2019 - 01/2018
1	Tuberculosis (Tuberculoses) 10/2022
1	Neglected Diseases 08/2022
1	Parasitic Diseases (Parasitic Disease) 01/2022
1	Stillbirth 01/2021
1	Spontaneous Abortion (Miscarriage) 01/2021
1	Maternal Death 01/2021
1	Coinfection 01/2021
1	Asymptomatic Diseases 01/2020
1	Cardiotoxicity 10/2018
1	Cutaneous Leishmaniasis 01/2018
1	Hypertrophy 01/2018
1	Pneumonia (Pneumonitis) 01/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 04/2013
1	Human Influenza (Influenza) 03/2013
1	Virus Diseases (Viral Diseases) 06/2011
1	Schistosomiasis mansoni 06/2011
1	Schistosomiasis (Bilharziasis) 06/2011

Drug/Important Bio-Agent (IBA)

11	miltefosine (Impavido)IBA 10/2022 - 01/2016
8	liposomal amphotericin B FDA Link 10/2022 - 01/2016
5	Pharmaceutical PreparationsIBA 01/2022 - 01/2015
5	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 11/2021 - 03/2017
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
3	Pentamidine (NebuPent)FDA LinkGeneric 01/2019 - 01/2015
3	Antimony Sodium Gluconate (Sodium, Stibogluconate)IBA 10/2018 - 01/2016
2	Amphotericin B (Amphotericin)FDA LinkGeneric 08/2022 - 01/2018
2	Propranolol (Inderal)FDA LinkGeneric 08/2021 - 02/2019
2	Ascorbic Acid (Vitamin C)FDA LinkGeneric 08/2021 - 02/2019
2	AntigensIBA 01/2020 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2019
2	alamandineIBA 01/2018 - 04/2013
1	Antiparasitic Agents (Antiparasitics)IBA 08/2022
1	Monoclonal AntibodiesIBA 01/2020
1	ElementsIBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	ProdrugsIBA 01/2018
1	ER 30346 (ravuconazole)IBA 01/2018
1	NeopterinIBA 01/2018
1	Angiotensin IIIBA 01/2018
1	benzonidazole (benznidazole)IBA 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2014
1	AntibodiesIBA 03/2013
1	Messenger RNA (mRNA)IBA 06/2011
1	Caspase 3 (Caspase-3)IBA 06/2011
1	Caspase 8 (Caspase-8)IBA 06/2011
1	Viral ProteinsIBA 06/2011
1	Praziquantel (Biltricide)FDA Link 06/2011

Therapy/Procedure

4	Therapeutics 10/2022 - 01/2014
1	Patient Admission (Patient Admissions) 01/2019
1	Injections 10/2018